Clinical Trial Update: Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated safety, tolerability and immunogenicity of two-dose heterologous Ebola vaccine regimens using Ad26.ZEBOV/MVA-BN-Filo; results were …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease

Drugs mentioned

• Ad26.ZEBOV/MVA-BN-Filo

Snippet

Sponsor: Janssen Vaccines & Prevention B.V. | Conditions: Hemorrhagic Fever, Ebola | Phase 2 | Status: COMPLETED | Results posted: 2022-02-18